MDR Clinical Evaluation Repeatedly Rejected? Longer Review Cycles Across Multiple Rounds | Exclusive Insights from CMEF Open Class
Views:84
Time:2026-11-03 11:05:05


Many medical device manufacturers pursuing EU CE-MDR certification get stuck at clinical evaluation (CEP / CER), facing repeated questions and multi-round re-assessments. Even with early submission, certification timelines keep stretching. One project went through 4 review rounds over 2 years, with 30 non-conformities initially identified. After the first re-submission, 18 non-conformities remained, and 60% of the raised issues were not genuinely closed after responses. This open class at Beijing CMEF breaks down Notified Body review requirements and countermeasures for EU CE clinical evaluation, combining real-world case studies, for enterprises planning to enter the EU market.



一、High-frequency Pitfalls Identified by Notified Bodies



Based on de-identified review records from multiple Notified Bodies, five categories of recurring issues are summarised:

(一)Confusing technical performance with clinical benefit
This is the most frequent error.
Wrong approach:Clinical benefit = compliance with ISO standards, low connection failure rate, qualified bonding strength.
MDR requirement:Clinical benefit must be realised on patients, representing positive outcomes meaningful to patients or patient management, rather than factory test results or hardware technical parameters.

Classic reviewer feedback: "This describes technical performance rather than measurable patient clinical endpoints."Numerous projects have been flagged for vague, general descriptions of clinical benefit without measurable indicators or supporting data.

Practical tip: Every statement in the intended purpose creates corresponding evidence obligations. 

Sort out the logical chain: Intended purpose → Indications → Target population → Use scenario → Clinical benefit → Clinical performance → Safety → External claims. Do not substitute clinical benefit with design or physical-chemical test results.


(二)SOTA(State-of-the-Art) written as a general literature review

Many manufacturers treat SOTA as an introduction to disease background or technology development history, which is a critical misunderstanding.
SOTA is not a popular science summary. It serves as the benchmark for evaluating your device, addressing three core questions::
  1. What is the current clinical practice? Treatment regimens, alternative devices, clinical guidelines
  2. What outcomes are achievable? Quantified performance, benefits, complications and adverse events with cited literature sources
  3. What benchmarks must our device meet? Deliver actionable safety & performance criteria

Common mistakes:
  • Only comparing against one reference product, ignoring alternative therapies and unmet clinical needs
  • No valid justification for comparator selection; mixing SOTA literature retrieval and equivalent device retrieval
  • Conflicting conclusions between cited literature and CER claims; simply deleting unfavourable literature to avoid discussion
Key takeaway:Deleting conflicting literature does not resolve issues. Conflicting or negative publications must be analysed and discussed explicitly within the document, instead of being removed.

Qualified SOTA deliverable:A benchmark comparison table with figures and references. It is recommended to build search strategies using the PICO framework, and fully retain search protocols, keywords, databases, inclusion/exclusion criteria and search screenshots so reviewers can reproduce your search process.

(三)Postponing clinical acceptance criteria; substituting clinical objectives with design requirements

"The performance targets specified, such as bonding strength, bending resistance and sealing performance, are design requirements, not clinical performance targets derived from SOTA."— Notified Body Review Comment

Numerous review comments converge on the same problem:
  • Acceptance criteria without numerical values, vague wording such as "no worse than similar devices"
  • Criteria sourced from internal factory inspection, not derived from SOTA clinical data
  • Criteria only explained in response letters to Notified Bodies, without being recorded in controlled CEP / CER files Reviewers assess controlled documents, not your response emails.

Correct workflow:
  1. Extract all external claims from instructions for use and intended purpose statements one by one
  2. Match each claim to corresponding clinical performance / safety parameters
  3. Trace parameter values back to SOTA benchmarks, with figures, units and calculation logic clearly stated
  4. Define supporting evidence types (literature / clinical investigation / PMCF)
  5. Embed all content into the main body of CEP and CER, not only within response documents
It is recommended to build a traceability matrix:Claim — Parameter — SOTA Source — Acceptance Criteria — Evidence Source, to expose gaps at a glance.

(四)Confusing similar devices with equivalent devices; equivalence assessment fails

Under MDR, similar ≠ equivalent! Only after a complete equivalence assessment (clinical, technical and biological comparability all satisfied), can data from an equivalent device be used for your clinical evaluation. Similar appearance and overlapping intended use alone do not permit direct reuse of third-party clinical data.

Many projects cite extensive literature from D3 (similar devices) and treat them as D2 (equivalent device) evidence, which gets rejected directly by reviewers, requiring a full change of clinical evaluation strategy.


(五)Superficial literature appraisal, only selecting favourable evidence
Literature appraisal cannot be limited to stacking references. Each publication requires three-dimensional assessment:Quality × Relevance × Contribution
  • Quality: Scientific validity of the study, sample size, endpoints, bias, statistical methodology
  • Relevance: Alignment with the device’s indications, target population and duration of use
  • Contribution: Whether it serves as key evidence or only supplementary support

Even for self-cited literature, negative findings cannot be ignored. After appraisal, clear conclusions must be formed: Pass / Fail / Insufficient evidence. For evidence gaps, propose solutions: supplementary literature, clinical investigation, PMCF plan, or narrowing the product claims. Do not include functions with insufficient evidence in the intended purpose. Restrict your claims to the boundary covered by available evidence.
二、What To Do & What To Avoid in MDR Clinical Evaluation



❌ Do NOT✅ Recommended
Collect piles of literature and consider the argument completedBuild a closed-loop logical evidence chain
Treat technical performance as clinical benefitClarify required evidence before drafting
Directly delete unfavourable literatureEvery acceptance criterion must be traceable back to SOTA
Only explain issues in response letters without updating controlled filesConsistent statements across CER, CEP, IFU and risk documents

The CER is not a writing task; it is a complete demonstration task. Clinical objectives, SOTA, clinical requirements, evidence appraisal and document consistency form a full chain. Reviewers will raise queries wherever the chain breaks.
三、Complete Evidence Chain



Clinical objective:What claims does the device make? Can the evidence support them?
SOTA benchmark:The industry’s current standard of care, real performance of comparable products
Clinical requirement:What needs to be demonstrated, and what quantified level must be achieved
Evidence appraisal:Whether existing evidence is sufficient; full discussion of negative results
Document consistency:CEP, CER, IFU and risk management files must tell the same coherent story
四、Self-check Checklist



  • MDR Annex XIV Part 1a clauses, line-by-line CEP self-check
  • MDCG 2020-13 Notified Body CER review template for pre-assessment
  • Claim traceability matrix to unify statements across all documents
  • PRISMA flow diagram to fully document literature screening workflow
五、Closing Remarks



Many manufacturers believe earlier submission is better. However, template-driven document drafting often traps you in repeated question-and-answer cycles. Solid planning, SOTA alignment and clinical requirement definition at the early stage is the real route to faster certification.For further enquiries, please contact Wiselink Group!

Contact Us
Fill Form
Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.